Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Switching to extended half-life products in Canada

× No keyword cloud information.

9 in total

1. Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.

Authors: Annarita Tagliaferri; Annalisa Matichecchia; Gianna F Rivolta; Federica Riccardi; Gabriele Quintavalle; Anna Benegiamo; Rossana Rossi; Antonio Coppola
Journal: Blood Transfus Date: 2019-11-04 Impact factor: 3.443

2. Comparison of Real-World Dose and Consumption for Two Extended Half-Life Recombinant Factor VIII Products for the Treatment of Hemophilia A in the United States.

Authors: Yanyu Wu; Shawn X Sun; Tao Fan
Journal: J Blood Med Date: 2022-09-24

3. Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data.

Authors: Ash Bullement; Samuel Thomas McMordie; Anthony James Hatswell; Nanxin Li; Koo Wilson
Journal: Pharmacoecon Open Date: 2020-03

Review 4. Recombinant factor VIII Fc for the treatment of haemophilia A.

Authors: Cedric Hermans; Maria Elisa Mancuso; Beatrice Nolan; K John Pasi
Journal: Eur J Haematol Date: 2021-03-31 Impact factor: 2.997

5. Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria.

Authors: Cihan Ay; Clemens Feistritzer; Joachim Rettl; Gerhard Schuster; Anna Vavrovsky; Leonard Perschy; Ingrid Pabinger
Journal: Sci Rep Date: 2021-06-21 Impact factor: 4.379

6. High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: Evidence from clinical trials and real-world practice.

Authors: Maria Elisa Mancuso; Johannes Oldenburg; Lisa Boggio; Gili Kenet; Anthony Chan; Carmen Altisent; Wilfried Seifert; Elena Santagostino
Journal: Haemophilia Date: 2020-06-15 Impact factor: 4.287

7. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study.

Authors: Beatrice Nolan; Johnny Mahlangu; Ingrid Pabinger; Guy Young; Barbara A Konkle; Chris Barnes; Keiji Nogami; Elena Santagostino; K John Pasi; Liane Khoo; Bent Winding; Huixing Yuan; Joachim Fruebis; Dan Rudin; Johannes Oldenburg
Journal: Haemophilia Date: 2020-03-30 Impact factor: 4.287

8. Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes.

Authors: Stacy E Croteau; Allison P Wheeler; Osman Khan; Kristina M Haley; Alexandra J Borst; Susan Lattimore; Cindy H T Yeung; Alfonso Iorio
Journal: Res Pract Thromb Haemost Date: 2020-02-06

9. Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc.

Authors: Marissa J M Traets; Kathelijn Fischer; Nanda Uitslager; Paul R van der Valk; Idske C L Kremer Hovinga; Lize F D van Vulpen; Roger E G Schutgens
Journal: TH Open Date: 2020-11-08

9 in total